世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 性腺機能低下症治療薬 - 世界市場シェア・ランキング、全体売上高・需要予測 2025-2031Hypogonadism Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 性腺機能低下症治療薬の世界市場規模は、2024年には3億7,500万米ドルと推定され、2031年には5億3,900万米ドルに再調整されると予測され、予測期間2025-2031年のCAGRは5.4%である。 性腺機能低下症の治療薬には2... もっと見る
※当ページの内容はウェブ更新時の情報です。 
サマリー性腺機能低下症治療薬の世界市場規模は、2024年には3億7,500万米ドルと推定され、2031年には5億3,900万米ドルに再調整されると予測され、予測期間2025-2031年のCAGRは5.4%である。性腺機能低下症の治療薬には2種類あり、1つはテストステロン補充療法薬、もう1つはゴナドトロピン治療薬で、男性の第二次性徴の正常な発達を維持し、生殖能力を回復させることを目的としている。 人口の増加、糖尿病や肥満などの慢性疾患の罹患率や有病率の上昇が市場成長の原動力となっている。臨床研究によると、60～80歳の男性のテストステロン値は、若い男性に比べてそれぞれ20％、80％低い。性腺機能低下症は60歳以上の男性に最も多い。日本、中国、米国などの国々では、老人人口の増加と不妊率の急上昇により、男性性腺機能低下症治療の需要が急増している。 本レポートでは、性腺機能低下症治療薬の世界市場について、地域別・国別、タイプ別、用途別の分析とともに、総販売量、販売収益、価格、主要企業の市場シェア、ランキングを中心に包括的に紹介することを目的としています。 性腺機能低下症治療薬の市場規模、推計、予測は、2024年を基準年として、2020年から2031年までの期間の履歴データと予測データを売上数量（K単位）と売上収益（百万ドル）で提供します。定量的・定性的分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、性腺機能低下症治療薬に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。 市場区分 企業別 アラガン アッヴィ エンド・ファーマシューティカルズ ファイザー クララス・セラピューティクス アイトゥ・バイオサイエンス社 アンタレス・ファーマ アップシャー・スミス・ラボラトリーズ社 北京双和製薬有限公司 天津金耀アミノ酸有限公司 天津金耀アミノ酸有限公司 天津麗生薬有限公司 承徳九龍製薬有限公司 ハルビン製薬グループ 瀋陽科達医薬有限公司 浙江仙珠製薬有限公司 タイプ別セグメント 注射剤 カプセル 用途別セグメント 病院 薬局 専門クリニック その他 地域別 北米 アメリカ カナダ アジア太平洋 中国 日本 韓国 東南アジア インド オーストラリア その他のアジア太平洋地域 ヨーロッパ ドイツ フランス 英国 イタリア オランダ 北欧諸国 その他のヨーロッパ ラテンアメリカ メキシコ ブラジル その他のラテンアメリカ 中東・アフリカ トルコ サウジアラビア アラブ首長国連邦 その他のMEA 各章の概要 第1章： レポートの対象範囲、世界の総市場規模（金額、数量、価格）を紹介します。また本章では、市場ダイナミクス、市場の最新動向、市場の促進要因と制限要因、業界メーカーが直面する課題とリスク、業界の関連政策の分析を提供します。 第2章 性腺機能低下症治療薬メーカーの競争環境、価格、売上高、市場シェア、最新の開発計画、合併・買収情報などを詳細に分析します。 第3章：各種市場セグメントをタイプ別に分析し、各市場セグメントの市場規模と発展可能性を網羅し、読者が各市場セグメントのブルーオーシャン市場を見つけやすくします。 第4章：用途別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。 第5章：性腺機能低下症治療薬の地域別売上高、収益。各地域の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、将来の発展展望、市場空間、市場規模を紹介しています。 第6章：国別性腺機能低下症治療薬の売上高、収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。 第7章：主要企業のプロフィールを提供し、製品の売上高、収益、価格、粗利益率、製品紹介、最近の開発など、市場における主要企業の基本的な状況を詳細に紹介する。 第8章：産業の上流と下流を含む産業チェーンの分析。 第9章：結論 目次1 Market Overview1.1 Hypogonadism Drug Product Introduction 1.2 Global Hypogonadism Drug Market Size Forecast 1.2.1 Global Hypogonadism Drug Sales Value (2020-2031) 1.2.2 Global Hypogonadism Drug Sales Volume (2020-2031) 1.2.3 Global Hypogonadism Drug Sales Price (2020-2031) 1.3 Hypogonadism Drug Market Trends & Drivers 1.3.1 Hypogonadism Drug Industry Trends 1.3.2 Hypogonadism Drug Market Drivers & Opportunity 1.3.3 Hypogonadism Drug Market Challenges 1.3.4 Hypogonadism Drug Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Hypogonadism Drug Players Revenue Ranking (2024) 2.2 Global Hypogonadism Drug Revenue by Company (2020-2025) 2.3 Global Hypogonadism Drug Players Sales Volume Ranking (2024) 2.4 Global Hypogonadism Drug Sales Volume by Company Players (2020-2025) 2.5 Global Hypogonadism Drug Average Price by Company (2020-2025) 2.6 Key Manufacturers Hypogonadism Drug Manufacturing Base and Headquarters 2.7 Key Manufacturers Hypogonadism Drug Product Offered 2.8 Key Manufacturers Time to Begin Mass Production of Hypogonadism Drug 2.9 Hypogonadism Drug Market Competitive Analysis 2.9.1 Hypogonadism Drug Market Concentration Rate (2020-2025) 2.9.2 Global 5 and 10 Largest Manufacturers by Hypogonadism Drug Revenue in 2024 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hypogonadism Drug as of 2024) 2.10 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Injection 3.1.2 Capsule 3.2 Global Hypogonadism Drug Sales Value by Type 3.2.1 Global Hypogonadism Drug Sales Value by Type (2020 VS 2024 VS 2031) 3.2.2 Global Hypogonadism Drug Sales Value, by Type (2020-2031) 3.2.3 Global Hypogonadism Drug Sales Value, by Type (%) (2020-2031) 3.3 Global Hypogonadism Drug Sales Volume by Type 3.3.1 Global Hypogonadism Drug Sales Volume by Type (2020 VS 2024 VS 2031) 3.3.2 Global Hypogonadism Drug Sales Volume, by Type (2020-2031) 3.3.3 Global Hypogonadism Drug Sales Volume, by Type (%) (2020-2031) 3.4 Global Hypogonadism Drug Average Price by Type (2020-2031) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Hospital 4.1.2 Pharmacy 4.1.3 Specialist Clinic 4.1.4 Others 4.2 Global Hypogonadism Drug Sales Value by Application 4.2.1 Global Hypogonadism Drug Sales Value by Application (2020 VS 2024 VS 2031) 4.2.2 Global Hypogonadism Drug Sales Value, by Application (2020-2031) 4.2.3 Global Hypogonadism Drug Sales Value, by Application (%) (2020-2031) 4.3 Global Hypogonadism Drug Sales Volume by Application 4.3.1 Global Hypogonadism Drug Sales Volume by Application (2020 VS 2024 VS 2031) 4.3.2 Global Hypogonadism Drug Sales Volume, by Application (2020-2031) 4.3.3 Global Hypogonadism Drug Sales Volume, by Application (%) (2020-2031) 4.4 Global Hypogonadism Drug Average Price by Application (2020-2031) 5 Segmentation by Region 5.1 Global Hypogonadism Drug Sales Value by Region 5.1.1 Global Hypogonadism Drug Sales Value by Region: 2020 VS 2024 VS 2031 5.1.2 Global Hypogonadism Drug Sales Value by Region (2020-2025) 5.1.3 Global Hypogonadism Drug Sales Value by Region (2026-2031) 5.1.4 Global Hypogonadism Drug Sales Value by Region (%), (2020-2031) 5.2 Global Hypogonadism Drug Sales Volume by Region 5.2.1 Global Hypogonadism Drug Sales Volume by Region: 2020 VS 2024 VS 2031 5.2.2 Global Hypogonadism Drug Sales Volume by Region (2020-2025) 5.2.3 Global Hypogonadism Drug Sales Volume by Region (2026-2031) 5.2.4 Global Hypogonadism Drug Sales Volume by Region (%), (2020-2031) 5.3 Global Hypogonadism Drug Average Price by Region (2020-2031) 5.4 North America 5.4.1 North America Hypogonadism Drug Sales Value, 2020-2031 5.4.2 North America Hypogonadism Drug Sales Value by Country (%), 2024 VS 2031 5.5 Europe 5.5.1 Europe Hypogonadism Drug Sales Value, 2020-2031 5.5.2 Europe Hypogonadism Drug Sales Value by Country (%), 2024 VS 2031 5.6 Asia Pacific 5.6.1 Asia Pacific Hypogonadism Drug Sales Value, 2020-2031 5.6.2 Asia Pacific Hypogonadism Drug Sales Value by Region (%), 2024 VS 2031 5.7 South America 5.7.1 South America Hypogonadism Drug Sales Value, 2020-2031 5.7.2 South America Hypogonadism Drug Sales Value by Country (%), 2024 VS 2031 5.8 Middle East & Africa 5.8.1 Middle East & Africa Hypogonadism Drug Sales Value, 2020-2031 5.8.2 Middle East & Africa Hypogonadism Drug Sales Value by Country (%), 2024 VS 2031 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Hypogonadism Drug Sales Value Growth Trends, 2020 VS 2024 VS 2031 6.2 Key Countries/Regions Hypogonadism Drug Sales Value 6.2.1 Key Countries/Regions Hypogonadism Drug Sales Value, 2020-2031 6.2.2 Key Countries/Regions Hypogonadism Drug Sales Volume, 2020-2031 6.3 United States 6.3.1 United States Hypogonadism Drug Sales Value, 2020-2031 6.3.2 United States Hypogonadism Drug Sales Value by Type (%), 2024 VS 2031 6.3.3 United States Hypogonadism Drug Sales Value by Application, 2024 VS 2031 6.4 Europe 6.4.1 Europe Hypogonadism Drug Sales Value, 2020-2031 6.4.2 Europe Hypogonadism Drug Sales Value by Type (%), 2024 VS 2031 6.4.3 Europe Hypogonadism Drug Sales Value by Application, 2024 VS 2031 6.5 China 6.5.1 China Hypogonadism Drug Sales Value, 2020-2031 6.5.2 China Hypogonadism Drug Sales Value by Type (%), 2024 VS 2031 6.5.3 China Hypogonadism Drug Sales Value by Application, 2024 VS 2031 6.6 Japan 6.6.1 Japan Hypogonadism Drug Sales Value, 2020-2031 6.6.2 Japan Hypogonadism Drug Sales Value by Type (%), 2024 VS 2031 6.6.3 Japan Hypogonadism Drug Sales Value by Application, 2024 VS 2031 6.7 South Korea 6.7.1 South Korea Hypogonadism Drug Sales Value, 2020-2031 6.7.2 South Korea Hypogonadism Drug Sales Value by Type (%), 2024 VS 2031 6.7.3 South Korea Hypogonadism Drug Sales Value by Application, 2024 VS 2031 6.8 Southeast Asia 6.8.1 Southeast Asia Hypogonadism Drug Sales Value, 2020-2031 6.8.2 Southeast Asia Hypogonadism Drug Sales Value by Type (%), 2024 VS 2031 6.8.3 Southeast Asia Hypogonadism Drug Sales Value by Application, 2024 VS 2031 6.9 India 6.9.1 India Hypogonadism Drug Sales Value, 2020-2031 6.9.2 India Hypogonadism Drug Sales Value by Type (%), 2024 VS 2031 6.9.3 India Hypogonadism Drug Sales Value by Application, 2024 VS 2031 7 Company Profiles 7.1 Allergan 7.1.1 Allergan Company Information 7.1.2 Allergan Introduction and Business Overview 7.1.3 Allergan Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.1.4 Allergan Hypogonadism Drug Product Offerings 7.1.5 Allergan Recent Development 7.2 AbbVie 7.2.1 AbbVie Company Information 7.2.2 AbbVie Introduction and Business Overview 7.2.3 AbbVie Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.2.4 AbbVie Hypogonadism Drug Product Offerings 7.2.5 AbbVie Recent Development 7.3 Endo Pharmaceuticals 7.3.1 Endo Pharmaceuticals Company Information 7.3.2 Endo Pharmaceuticals Introduction and Business Overview 7.3.3 Endo Pharmaceuticals Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.3.4 Endo Pharmaceuticals Hypogonadism Drug Product Offerings 7.3.5 Endo Pharmaceuticals Recent Development 7.4 Pfizer Inc. 7.4.1 Pfizer Inc. Company Information 7.4.2 Pfizer Inc. Introduction and Business Overview 7.4.3 Pfizer Inc. Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.4.4 Pfizer Inc. Hypogonadism Drug Product Offerings 7.4.5 Pfizer Inc. Recent Development 7.5 Clarus Therapeutics, Inc. 7.5.1 Clarus Therapeutics, Inc. Company Information 7.5.2 Clarus Therapeutics, Inc. Introduction and Business Overview 7.5.3 Clarus Therapeutics, Inc. Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.5.4 Clarus Therapeutics, Inc. Hypogonadism Drug Product Offerings 7.5.5 Clarus Therapeutics, Inc. Recent Development 7.6 Aytu BioScience, Inc. 7.6.1 Aytu BioScience, Inc. Company Information 7.6.2 Aytu BioScience, Inc. Introduction and Business Overview 7.6.3 Aytu BioScience, Inc. Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.6.4 Aytu BioScience, Inc. Hypogonadism Drug Product Offerings 7.6.5 Aytu BioScience, Inc. Recent Development 7.7 Antares Pharma 7.7.1 Antares Pharma Company Information 7.7.2 Antares Pharma Introduction and Business Overview 7.7.3 Antares Pharma Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.7.4 Antares Pharma Hypogonadism Drug Product Offerings 7.7.5 Antares Pharma Recent Development 7.8 Upsher-Smith Laboratories, Inc. 7.8.1 Upsher-Smith Laboratories, Inc. Company Information 7.8.2 Upsher-Smith Laboratories, Inc. Introduction and Business Overview 7.8.3 Upsher-Smith Laboratories, Inc. Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.8.4 Upsher-Smith Laboratories, Inc. Hypogonadism Drug Product Offerings 7.8.5 Upsher-Smith Laboratories, Inc. Recent Development 7.9 Beijing Shuanghe Pharmaceutical Co., Ltd 7.9.1 Beijing Shuanghe Pharmaceutical Co., Ltd Company Information 7.9.2 Beijing Shuanghe Pharmaceutical Co., Ltd Introduction and Business Overview 7.9.3 Beijing Shuanghe Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.9.4 Beijing Shuanghe Pharmaceutical Co., Ltd Hypogonadism Drug Product Offerings 7.9.5 Beijing Shuanghe Pharmaceutical Co., Ltd Recent Development 7.10 Tianjin Jinyao Amino Acid Co., Ltd 7.10.1 Tianjin Jinyao Amino Acid Co., Ltd Company Information 7.10.2 Tianjin Jinyao Amino Acid Co., Ltd Introduction and Business Overview 7.10.3 Tianjin Jinyao Amino Acid Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.10.4 Tianjin Jinyao Amino Acid Co., Ltd Hypogonadism Drug Product Offerings 7.10.5 Tianjin Jinyao Amino Acid Co., Ltd Recent Development 7.11 Shanghai General Pharmaceutical Co., Ltd 7.11.1 Shanghai General Pharmaceutical Co., Ltd Company Information 7.11.2 Shanghai General Pharmaceutical Co., Ltd Introduction and Business Overview 7.11.3 Shanghai General Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.11.4 Shanghai General Pharmaceutical Co., Ltd Hypogonadism Drug Product Offerings 7.11.5 Shanghai General Pharmaceutical Co., Ltd Recent Development 7.12 Tianjin Lisheng Pharmaceutical Co., Ltd 7.12.1 Tianjin Lisheng Pharmaceutical Co., Ltd Company Information 7.12.2 Tianjin Lisheng Pharmaceutical Co., Ltd Introduction and Business Overview 7.12.3 Tianjin Lisheng Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.12.4 Tianjin Lisheng Pharmaceutical Co., Ltd Hypogonadism Drug Product Offerings 7.12.5 Tianjin Lisheng Pharmaceutical Co., Ltd Recent Development 7.13 Chengde Jiulong Pharmaceutical Co., Ltd 7.13.1 Chengde Jiulong Pharmaceutical Co., Ltd Company Information 7.13.2 Chengde Jiulong Pharmaceutical Co., Ltd Introduction and Business Overview 7.13.3 Chengde Jiulong Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.13.4 Chengde Jiulong Pharmaceutical Co., Ltd Hypogonadism Drug Product Offerings 7.13.5 Chengde Jiulong Pharmaceutical Co., Ltd Recent Development 7.14 Harbin Pharmaceutical Group 7.14.1 Harbin Pharmaceutical Group Company Information 7.14.2 Harbin Pharmaceutical Group Introduction and Business Overview 7.14.3 Harbin Pharmaceutical Group Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.14.4 Harbin Pharmaceutical Group Hypogonadism Drug Product Offerings 7.14.5 Harbin Pharmaceutical Group Recent Development 7.15 Shenyang Keda Pharmaceutical Co., Ltd 7.15.1 Shenyang Keda Pharmaceutical Co., Ltd Company Information 7.15.2 Shenyang Keda Pharmaceutical Co., Ltd Introduction and Business Overview 7.15.3 Shenyang Keda Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.15.4 Shenyang Keda Pharmaceutical Co., Ltd Hypogonadism Drug Product Offerings 7.15.5 Shenyang Keda Pharmaceutical Co., Ltd Recent Development 7.16 Zhejiang Xianju Pharmaceutical Co., Ltd 7.16.1 Zhejiang Xianju Pharmaceutical Co., Ltd Company Information 7.16.2 Zhejiang Xianju Pharmaceutical Co., Ltd Introduction and Business Overview 7.16.3 Zhejiang Xianju Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.16.4 Zhejiang Xianju Pharmaceutical Co., Ltd Hypogonadism Drug Product Offerings 7.16.5 Zhejiang Xianju Pharmaceutical Co., Ltd Recent Development 8 Industry Chain Analysis 8.1 Hypogonadism Drug Industrial Chain 8.2 Hypogonadism Drug Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Hypogonadism Drug Sales Model 8.5.2 Sales Channel 8.5.3 Hypogonadism Drug Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.1.1 Research Programs/Design 10.1.1.2 Market Size Estimation 10.1.1.3 Market Breakdown and Data Triangulation 10.1.2 Data Source 10.1.2.1 Secondary Sources 10.1.2.2 Primary Sources 10.2 Author Details 10.3 Disclaimer
SummaryThe global market for Hypogonadism Drug was estimated to be worth US$ 3750 million in 2024 and is forecast to a readjusted size of US$ 5391 million by 2031 with a CAGR of 5.4% during the forecast period 2025-2031. Table of Contents1 Market Overview1.1 Hypogonadism Drug Product Introduction 1.2 Global Hypogonadism Drug Market Size Forecast 1.2.1 Global Hypogonadism Drug Sales Value (2020-2031) 1.2.2 Global Hypogonadism Drug Sales Volume (2020-2031) 1.2.3 Global Hypogonadism Drug Sales Price (2020-2031) 1.3 Hypogonadism Drug Market Trends & Drivers 1.3.1 Hypogonadism Drug Industry Trends 1.3.2 Hypogonadism Drug Market Drivers & Opportunity 1.3.3 Hypogonadism Drug Market Challenges 1.3.4 Hypogonadism Drug Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Hypogonadism Drug Players Revenue Ranking (2024) 2.2 Global Hypogonadism Drug Revenue by Company (2020-2025) 2.3 Global Hypogonadism Drug Players Sales Volume Ranking (2024) 2.4 Global Hypogonadism Drug Sales Volume by Company Players (2020-2025) 2.5 Global Hypogonadism Drug Average Price by Company (2020-2025) 2.6 Key Manufacturers Hypogonadism Drug Manufacturing Base and Headquarters 2.7 Key Manufacturers Hypogonadism Drug Product Offered 2.8 Key Manufacturers Time to Begin Mass Production of Hypogonadism Drug 2.9 Hypogonadism Drug Market Competitive Analysis 2.9.1 Hypogonadism Drug Market Concentration Rate (2020-2025) 2.9.2 Global 5 and 10 Largest Manufacturers by Hypogonadism Drug Revenue in 2024 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hypogonadism Drug as of 2024) 2.10 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Injection 3.1.2 Capsule 3.2 Global Hypogonadism Drug Sales Value by Type 3.2.1 Global Hypogonadism Drug Sales Value by Type (2020 VS 2024 VS 2031) 3.2.2 Global Hypogonadism Drug Sales Value, by Type (2020-2031) 3.2.3 Global Hypogonadism Drug Sales Value, by Type (%) (2020-2031) 3.3 Global Hypogonadism Drug Sales Volume by Type 3.3.1 Global Hypogonadism Drug Sales Volume by Type (2020 VS 2024 VS 2031) 3.3.2 Global Hypogonadism Drug Sales Volume, by Type (2020-2031) 3.3.3 Global Hypogonadism Drug Sales Volume, by Type (%) (2020-2031) 3.4 Global Hypogonadism Drug Average Price by Type (2020-2031) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Hospital 4.1.2 Pharmacy 4.1.3 Specialist Clinic 4.1.4 Others 4.2 Global Hypogonadism Drug Sales Value by Application 4.2.1 Global Hypogonadism Drug Sales Value by Application (2020 VS 2024 VS 2031) 4.2.2 Global Hypogonadism Drug Sales Value, by Application (2020-2031) 4.2.3 Global Hypogonadism Drug Sales Value, by Application (%) (2020-2031) 4.3 Global Hypogonadism Drug Sales Volume by Application 4.3.1 Global Hypogonadism Drug Sales Volume by Application (2020 VS 2024 VS 2031) 4.3.2 Global Hypogonadism Drug Sales Volume, by Application (2020-2031) 4.3.3 Global Hypogonadism Drug Sales Volume, by Application (%) (2020-2031) 4.4 Global Hypogonadism Drug Average Price by Application (2020-2031) 5 Segmentation by Region 5.1 Global Hypogonadism Drug Sales Value by Region 5.1.1 Global Hypogonadism Drug Sales Value by Region: 2020 VS 2024 VS 2031 5.1.2 Global Hypogonadism Drug Sales Value by Region (2020-2025) 5.1.3 Global Hypogonadism Drug Sales Value by Region (2026-2031) 5.1.4 Global Hypogonadism Drug Sales Value by Region (%), (2020-2031) 5.2 Global Hypogonadism Drug Sales Volume by Region 5.2.1 Global Hypogonadism Drug Sales Volume by Region: 2020 VS 2024 VS 2031 5.2.2 Global Hypogonadism Drug Sales Volume by Region (2020-2025) 5.2.3 Global Hypogonadism Drug Sales Volume by Region (2026-2031) 5.2.4 Global Hypogonadism Drug Sales Volume by Region (%), (2020-2031) 5.3 Global Hypogonadism Drug Average Price by Region (2020-2031) 5.4 North America 5.4.1 North America Hypogonadism Drug Sales Value, 2020-2031 5.4.2 North America Hypogonadism Drug Sales Value by Country (%), 2024 VS 2031 5.5 Europe 5.5.1 Europe Hypogonadism Drug Sales Value, 2020-2031 5.5.2 Europe Hypogonadism Drug Sales Value by Country (%), 2024 VS 2031 5.6 Asia Pacific 5.6.1 Asia Pacific Hypogonadism Drug Sales Value, 2020-2031 5.6.2 Asia Pacific Hypogonadism Drug Sales Value by Region (%), 2024 VS 2031 5.7 South America 5.7.1 South America Hypogonadism Drug Sales Value, 2020-2031 5.7.2 South America Hypogonadism Drug Sales Value by Country (%), 2024 VS 2031 5.8 Middle East & Africa 5.8.1 Middle East & Africa Hypogonadism Drug Sales Value, 2020-2031 5.8.2 Middle East & Africa Hypogonadism Drug Sales Value by Country (%), 2024 VS 2031 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Hypogonadism Drug Sales Value Growth Trends, 2020 VS 2024 VS 2031 6.2 Key Countries/Regions Hypogonadism Drug Sales Value 6.2.1 Key Countries/Regions Hypogonadism Drug Sales Value, 2020-2031 6.2.2 Key Countries/Regions Hypogonadism Drug Sales Volume, 2020-2031 6.3 United States 6.3.1 United States Hypogonadism Drug Sales Value, 2020-2031 6.3.2 United States Hypogonadism Drug Sales Value by Type (%), 2024 VS 2031 6.3.3 United States Hypogonadism Drug Sales Value by Application, 2024 VS 2031 6.4 Europe 6.4.1 Europe Hypogonadism Drug Sales Value, 2020-2031 6.4.2 Europe Hypogonadism Drug Sales Value by Type (%), 2024 VS 2031 6.4.3 Europe Hypogonadism Drug Sales Value by Application, 2024 VS 2031 6.5 China 6.5.1 China Hypogonadism Drug Sales Value, 2020-2031 6.5.2 China Hypogonadism Drug Sales Value by Type (%), 2024 VS 2031 6.5.3 China Hypogonadism Drug Sales Value by Application, 2024 VS 2031 6.6 Japan 6.6.1 Japan Hypogonadism Drug Sales Value, 2020-2031 6.6.2 Japan Hypogonadism Drug Sales Value by Type (%), 2024 VS 2031 6.6.3 Japan Hypogonadism Drug Sales Value by Application, 2024 VS 2031 6.7 South Korea 6.7.1 South Korea Hypogonadism Drug Sales Value, 2020-2031 6.7.2 South Korea Hypogonadism Drug Sales Value by Type (%), 2024 VS 2031 6.7.3 South Korea Hypogonadism Drug Sales Value by Application, 2024 VS 2031 6.8 Southeast Asia 6.8.1 Southeast Asia Hypogonadism Drug Sales Value, 2020-2031 6.8.2 Southeast Asia Hypogonadism Drug Sales Value by Type (%), 2024 VS 2031 6.8.3 Southeast Asia Hypogonadism Drug Sales Value by Application, 2024 VS 2031 6.9 India 6.9.1 India Hypogonadism Drug Sales Value, 2020-2031 6.9.2 India Hypogonadism Drug Sales Value by Type (%), 2024 VS 2031 6.9.3 India Hypogonadism Drug Sales Value by Application, 2024 VS 2031 7 Company Profiles 7.1 Allergan 7.1.1 Allergan Company Information 7.1.2 Allergan Introduction and Business Overview 7.1.3 Allergan Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.1.4 Allergan Hypogonadism Drug Product Offerings 7.1.5 Allergan Recent Development 7.2 AbbVie 7.2.1 AbbVie Company Information 7.2.2 AbbVie Introduction and Business Overview 7.2.3 AbbVie Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.2.4 AbbVie Hypogonadism Drug Product Offerings 7.2.5 AbbVie Recent Development 7.3 Endo Pharmaceuticals 7.3.1 Endo Pharmaceuticals Company Information 7.3.2 Endo Pharmaceuticals Introduction and Business Overview 7.3.3 Endo Pharmaceuticals Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.3.4 Endo Pharmaceuticals Hypogonadism Drug Product Offerings 7.3.5 Endo Pharmaceuticals Recent Development 7.4 Pfizer Inc. 7.4.1 Pfizer Inc. Company Information 7.4.2 Pfizer Inc. Introduction and Business Overview 7.4.3 Pfizer Inc. Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.4.4 Pfizer Inc. Hypogonadism Drug Product Offerings 7.4.5 Pfizer Inc. Recent Development 7.5 Clarus Therapeutics, Inc. 7.5.1 Clarus Therapeutics, Inc. Company Information 7.5.2 Clarus Therapeutics, Inc. Introduction and Business Overview 7.5.3 Clarus Therapeutics, Inc. Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.5.4 Clarus Therapeutics, Inc. Hypogonadism Drug Product Offerings 7.5.5 Clarus Therapeutics, Inc. Recent Development 7.6 Aytu BioScience, Inc. 7.6.1 Aytu BioScience, Inc. Company Information 7.6.2 Aytu BioScience, Inc. Introduction and Business Overview 7.6.3 Aytu BioScience, Inc. Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.6.4 Aytu BioScience, Inc. Hypogonadism Drug Product Offerings 7.6.5 Aytu BioScience, Inc. Recent Development 7.7 Antares Pharma 7.7.1 Antares Pharma Company Information 7.7.2 Antares Pharma Introduction and Business Overview 7.7.3 Antares Pharma Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.7.4 Antares Pharma Hypogonadism Drug Product Offerings 7.7.5 Antares Pharma Recent Development 7.8 Upsher-Smith Laboratories, Inc. 7.8.1 Upsher-Smith Laboratories, Inc. Company Information 7.8.2 Upsher-Smith Laboratories, Inc. Introduction and Business Overview 7.8.3 Upsher-Smith Laboratories, Inc. Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.8.4 Upsher-Smith Laboratories, Inc. Hypogonadism Drug Product Offerings 7.8.5 Upsher-Smith Laboratories, Inc. Recent Development 7.9 Beijing Shuanghe Pharmaceutical Co., Ltd 7.9.1 Beijing Shuanghe Pharmaceutical Co., Ltd Company Information 7.9.2 Beijing Shuanghe Pharmaceutical Co., Ltd Introduction and Business Overview 7.9.3 Beijing Shuanghe Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.9.4 Beijing Shuanghe Pharmaceutical Co., Ltd Hypogonadism Drug Product Offerings 7.9.5 Beijing Shuanghe Pharmaceutical Co., Ltd Recent Development 7.10 Tianjin Jinyao Amino Acid Co., Ltd 7.10.1 Tianjin Jinyao Amino Acid Co., Ltd Company Information 7.10.2 Tianjin Jinyao Amino Acid Co., Ltd Introduction and Business Overview 7.10.3 Tianjin Jinyao Amino Acid Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.10.4 Tianjin Jinyao Amino Acid Co., Ltd Hypogonadism Drug Product Offerings 7.10.5 Tianjin Jinyao Amino Acid Co., Ltd Recent Development 7.11 Shanghai General Pharmaceutical Co., Ltd 7.11.1 Shanghai General Pharmaceutical Co., Ltd Company Information 7.11.2 Shanghai General Pharmaceutical Co., Ltd Introduction and Business Overview 7.11.3 Shanghai General Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.11.4 Shanghai General Pharmaceutical Co., Ltd Hypogonadism Drug Product Offerings 7.11.5 Shanghai General Pharmaceutical Co., Ltd Recent Development 7.12 Tianjin Lisheng Pharmaceutical Co., Ltd 7.12.1 Tianjin Lisheng Pharmaceutical Co., Ltd Company Information 7.12.2 Tianjin Lisheng Pharmaceutical Co., Ltd Introduction and Business Overview 7.12.3 Tianjin Lisheng Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.12.4 Tianjin Lisheng Pharmaceutical Co., Ltd Hypogonadism Drug Product Offerings 7.12.5 Tianjin Lisheng Pharmaceutical Co., Ltd Recent Development 7.13 Chengde Jiulong Pharmaceutical Co., Ltd 7.13.1 Chengde Jiulong Pharmaceutical Co., Ltd Company Information 7.13.2 Chengde Jiulong Pharmaceutical Co., Ltd Introduction and Business Overview 7.13.3 Chengde Jiulong Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.13.4 Chengde Jiulong Pharmaceutical Co., Ltd Hypogonadism Drug Product Offerings 7.13.5 Chengde Jiulong Pharmaceutical Co., Ltd Recent Development 7.14 Harbin Pharmaceutical Group 7.14.1 Harbin Pharmaceutical Group Company Information 7.14.2 Harbin Pharmaceutical Group Introduction and Business Overview 7.14.3 Harbin Pharmaceutical Group Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.14.4 Harbin Pharmaceutical Group Hypogonadism Drug Product Offerings 7.14.5 Harbin Pharmaceutical Group Recent Development 7.15 Shenyang Keda Pharmaceutical Co., Ltd 7.15.1 Shenyang Keda Pharmaceutical Co., Ltd Company Information 7.15.2 Shenyang Keda Pharmaceutical Co., Ltd Introduction and Business Overview 7.15.3 Shenyang Keda Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.15.4 Shenyang Keda Pharmaceutical Co., Ltd Hypogonadism Drug Product Offerings 7.15.5 Shenyang Keda Pharmaceutical Co., Ltd Recent Development 7.16 Zhejiang Xianju Pharmaceutical Co., Ltd 7.16.1 Zhejiang Xianju Pharmaceutical Co., Ltd Company Information 7.16.2 Zhejiang Xianju Pharmaceutical Co., Ltd Introduction and Business Overview 7.16.3 Zhejiang Xianju Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025) 7.16.4 Zhejiang Xianju Pharmaceutical Co., Ltd Hypogonadism Drug Product Offerings 7.16.5 Zhejiang Xianju Pharmaceutical Co., Ltd Recent Development 8 Industry Chain Analysis 8.1 Hypogonadism Drug Industrial Chain 8.2 Hypogonadism Drug Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Hypogonadism Drug Sales Model 8.5.2 Sales Channel 8.5.3 Hypogonadism Drug Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.1.1 Research Programs/Design 10.1.1.2 Market Size Estimation 10.1.1.3 Market Breakdown and Data Triangulation 10.1.2 Data Source 10.1.2.1 Secondary Sources 10.1.2.2 Primary Sources 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療/ヘルスケア）の最新刊レポート
QYResearch社の医薬・ヘルスケア分野での最新刊レポート
本レポートと同じKEY WORD（drug）の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
